The changing landscape of the clinical value of the PM/Scl autoantibody system

doi:10.1186/ar2646

Arthritis Research & Therapy

Volume 11
Issue 2

Viewing options:

Abstract
Full text
PDF (44KB)

Associated material:

Related literature:

Articles citing this article
on Google Scholar
on ISI Web of Science
on PubMed Central
Other articles by authors
on Google Scholar

Mahler M
Fritzler MJ

on PubMed

Mahler M
Fritzler MJ
Related articles/pages
on Google

on Google Scholar

on PubMed

Tools:

Post to:

Editorial

The changing landscape of the clinical value of the PM/Scl autoantibody system

Michael Mahler¹^* and Marvin J Fritzler²^*

¹Dr Fooke Laboratorien GmbH, Mainstr., 41469 Neuss, Germany

²Faculty of Medicine, University of Calgary, Hospital Dr NW, Calgary, Alberta, Canada T2N 4N1

author email corresponding author email* Contributed equally

Arthritis Research & Therapy 2009, 11:106doi:10.1186/ar2646


Published:	26 March 2009

See related research article by Hanke et al., http://arthritis-research.com/content/11/1/R22

Abstract

Autoantibodies to the polymyositis/scleroderma (PM/Scl) complex have been associated with systemic sclerosis and PM/Scl overlap syndrome. The report of Hanke and colleagues in a recent issue of Arthritis Research and Therapy is the first to describe the separate evaluation of anti-PM/Scl-75c and PM/Scl-100 autoantibodies and their relationship to clinical manifestations of systemic sclerosis. Several observations are of paramount interest, but are not in general agreement with earlier studies. These include the prevalence of anti-PM/Scl antibodies in systemic sclerosis, the association with certain clinical manifestations and prognosis of patients. This report will hopefully trigger systematic multi-centre studies to confirm and/or elucidate the novel line immunoassay and clinical associations.